MX2019009954A - Metodos para el tratamiento de pacientes con neoplasias malignas hematologicas. - Google Patents
Metodos para el tratamiento de pacientes con neoplasias malignas hematologicas.Info
- Publication number
- MX2019009954A MX2019009954A MX2019009954A MX2019009954A MX2019009954A MX 2019009954 A MX2019009954 A MX 2019009954A MX 2019009954 A MX2019009954 A MX 2019009954A MX 2019009954 A MX2019009954 A MX 2019009954A MX 2019009954 A MX2019009954 A MX 2019009954A
- Authority
- MX
- Mexico
- Prior art keywords
- present disclosure
- methods
- wild
- treating patients
- further relates
- Prior art date
Links
- 208000002250 Hematologic Neoplasms Diseases 0.000 title 1
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- -1 2,3-dihydro-isoindole-1-one compound Chemical class 0.000 abstract 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102100029823 Tyrosine-protein kinase BTK Human genes 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 108010003374 fms-Like Tyrosine Kinase 3 Proteins 0.000 abstract 1
- 230000002489 hematologic effect Effects 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762461584P | 2017-02-21 | 2017-02-21 | |
| US201762578948P | 2017-10-30 | 2017-10-30 | |
| PCT/US2018/018951 WO2018156578A1 (en) | 2017-02-21 | 2018-02-21 | Methods for treating patients with hematologic malignancies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019009954A true MX2019009954A (es) | 2019-12-19 |
Family
ID=63253344
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019009954A MX2019009954A (es) | 2017-02-21 | 2018-02-21 | Metodos para el tratamiento de pacientes con neoplasias malignas hematologicas. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20180344702A1 (enExample) |
| EP (1) | EP3585778A4 (enExample) |
| JP (2) | JP7227913B2 (enExample) |
| KR (1) | KR20190128646A (enExample) |
| CN (1) | CN110621665A (enExample) |
| AU (2) | AU2018225539B2 (enExample) |
| CA (1) | CA3054196A1 (enExample) |
| IL (1) | IL268736A (enExample) |
| MX (1) | MX2019009954A (enExample) |
| TW (1) | TWI821174B (enExample) |
| WO (1) | WO2018156578A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3559038B1 (en) | 2016-12-21 | 2022-12-14 | The United States of America as represented by The Secretary Department of Health and Human Services | Human monoclonal antibodies specific for flt3 and uses thereof |
| KR101954370B1 (ko) | 2018-07-25 | 2019-03-05 | 한미약품 주식회사 | 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물 |
| US20200171001A1 (en) * | 2018-11-30 | 2020-06-04 | Aptose Biosciences Inc. | Combination therapy with 2,3-dihydro-isoindole-1-one compounds and methods for treating patients with various mutations |
| BR112021016522A2 (pt) | 2019-02-22 | 2021-10-26 | Hanmi Pharm. Co., Ltd. | Composição farmacêutica para o tratamento da leucemia mieloide aguda |
| EP3991733A4 (en) | 2019-06-27 | 2023-07-05 | Hanmi Pharm. Co., Ltd. | Pharmaceutical composition for treating acute myeloid leukemia, containing flt3 inhibitor and chemotherapeutic agents |
| CN114828842A (zh) * | 2019-10-21 | 2022-07-29 | 理森制药股份公司 | 用于治疗急性髓系白血病的包含dhodh抑制剂的组合物 |
| US20240091226A1 (en) * | 2021-01-05 | 2024-03-21 | Sumitomo Pharma Oncology, Inc. | Forms and Formulations Of A Tyrosine Kinase Non-Receptor 1 (TNK1) Inhibitor |
| CN117295737A (zh) * | 2021-03-05 | 2023-12-26 | 林伯士萨顿公司 | Hpk1拮抗剂和其用途 |
| WO2022213062A1 (en) | 2021-03-29 | 2022-10-06 | Nimbus Saturn, Inc. | Hpk1 antagonists and uses thereof |
| WO2023129667A1 (en) | 2021-12-30 | 2023-07-06 | Biomea Fusion, Inc. | Pyrazine compounds as inhibitors of flt3 |
| CN120857931A (zh) * | 2022-12-10 | 2025-10-28 | 艾普托斯生物科学公司 | 用于治疗患有血液学恶性病的患者的方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012047017A2 (ko) * | 2010-10-05 | 2012-04-12 | 크리스탈지노믹스(주) | 2,3-디히드로-이소인돌-1-온 유도체 및 이를 포함하는 조성물 |
| DK2940014T3 (en) * | 2012-12-28 | 2018-12-10 | Crystalgenomics Inc | 2,3-DIHYDRO-ISOINDOL-1-ON DERIVATIVE AS BTK KINase INHIBITORS AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME |
| US10463658B2 (en) * | 2013-10-25 | 2019-11-05 | Videra Pharmaceuticals, Llc | Method of inhibiting FLT3 kinase |
| EP3062809B1 (en) * | 2013-10-31 | 2020-07-08 | Biokine Therapeutics Ltd. | A cxcr4 peptide inhibitor for use in treating acute myeloid leukemia with a flt3 mutation |
-
2018
- 2018-02-21 KR KR1020197027330A patent/KR20190128646A/ko not_active Ceased
- 2018-02-21 TW TW107105790A patent/TWI821174B/zh active
- 2018-02-21 MX MX2019009954A patent/MX2019009954A/es unknown
- 2018-02-21 JP JP2019545304A patent/JP7227913B2/ja active Active
- 2018-02-21 AU AU2018225539A patent/AU2018225539B2/en active Active
- 2018-02-21 EP EP18756992.6A patent/EP3585778A4/en not_active Withdrawn
- 2018-02-21 WO PCT/US2018/018951 patent/WO2018156578A1/en not_active Ceased
- 2018-02-21 CA CA3054196A patent/CA3054196A1/en not_active Withdrawn
- 2018-02-21 CN CN201880018924.0A patent/CN110621665A/zh active Pending
- 2018-02-21 US US15/901,439 patent/US20180344702A1/en not_active Abandoned
-
2019
- 2019-08-15 IL IL26873619A patent/IL268736A/en unknown
-
2022
- 2022-02-18 US US17/675,469 patent/US20230012148A1/en not_active Abandoned
- 2022-10-10 AU AU2022252696A patent/AU2022252696B2/en not_active Expired - Fee Related
- 2022-12-12 JP JP2022197816A patent/JP7431309B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN110621665A (zh) | 2019-12-27 |
| AU2018225539B2 (en) | 2022-07-14 |
| EP3585778A4 (en) | 2020-12-02 |
| TWI821174B (zh) | 2023-11-11 |
| IL268736A (en) | 2019-10-31 |
| AU2022252696B2 (en) | 2025-01-30 |
| TW201842906A (zh) | 2018-12-16 |
| JP2023022330A (ja) | 2023-02-14 |
| US20180344702A1 (en) | 2018-12-06 |
| CA3054196A1 (en) | 2018-08-30 |
| WO2018156578A1 (en) | 2018-08-30 |
| AU2022252696A1 (en) | 2022-11-03 |
| KR20190128646A (ko) | 2019-11-18 |
| US20230012148A1 (en) | 2023-01-12 |
| JP2020508313A (ja) | 2020-03-19 |
| AU2018225539A1 (en) | 2019-09-05 |
| JP7431309B2 (ja) | 2024-02-14 |
| JP7227913B2 (ja) | 2023-02-22 |
| EP3585778A1 (en) | 2020-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022002415A (es) | Metodos de tratamiento del cancer de mama con derivados de tetrahidronaftaleno como degradadores del receptor de estrogenos. | |
| ZA202201499B (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
| PH12016501394A1 (en) | Compounds for treating patients with ros1 mutant cancer cells | |
| PH12017500146A1 (en) | 2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof | |
| MX393711B (es) | Derivados de tiocarbamato como inhibidores de a2a y metodos para su uso en el tratamiento de canceres | |
| MX393599B (es) | Rad1901 para usarse en el tratamiento de cancer en sujetos con cancer positivo a receptor de estrogeno alfa resistente a farmaco | |
| EA033689B9 (ru) | Ингибиторы g12c kras | |
| PH12016502354A1 (en) | Pharmaceutical composition | |
| PH12015501326A1 (en) | 2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer | |
| TW201613875A (en) | EGFR inhibitors, their preparation and their use thereof | |
| MY186126A (en) | Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor | |
| ZA202306172B (en) | Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase | |
| GEP20247627B (en) | Macrocyclic compounds as sting agonists and methods and uses thereof | |
| MX2016007311A (es) | Metodos para tratar canceres. | |
| MX2022009612A (es) | Combinacion de bi853520 con farmacos quimioterapeuticos. | |
| TW201613589A (en) | Combination methods for treating cancers | |
| BR112021006318A2 (pt) | terapia de combinação para o tratamento de câncer | |
| ZA202102438B (en) | Melflufen dosage regimens for cancer | |
| MX2019009501A (es) | Compuestos de amino piridina utiles como inhibidores de ssao. | |
| MX2023013715A (es) | Regímenes de dosis de ecubectedina. | |
| NZ748592A (en) | Treatment for parkinson’s disease | |
| PH12020551495A1 (en) | Compounds with anti-tumor activity against cancer cells bearing her2 exon 19 mutations | |
| MX2020010618A (es) | Derivados de pirazolotriazolopiriminina como antagonista del receptor a2a. | |
| PH12021552110A1 (en) | Compounds with anti-tumor activity against cancer cells bearing her2 exon 21 insertions | |
| MX2018006776A (es) | Usos de pirimido-piridazinonas para tratar el cancer. |